耳鼻と臨床

抄録を表示する抄録を非表示にする

Cellular immune competence was examined using three skin sensitivity tests (DNCB, PPD and PHA) in 121 cases of maxillary cancer and 110 with benign sinus disease, as control, since September 1976. One of four immunopotentiators (schizophyllan, levamisole, Krestin and OK-432) was administered to 61 cancer patients who showed negative response to more than one skin sensitivity tests. Each of these skin tests has advantage and disadvantage, but they may be useful as clinical indices. Any of these immunopotentiators could improve the skin tests, which reflected good clinical prognosis. Recurrence of the cancerous symptoms was found in 35% of the patients who were administered immunopotentiator (s), if necessary by examining skin sensitivity tests, after the first treatment (combined therapy; surgery, irradiation and regional chemotherapy). On the other hand, recurrence was found in 60 % of the patients who were not administered immunopotentiators initially.

抄録全体を表示

PDF形式でダウンロード (4323K)

J-STAGEへの登録はこちら（無料）